ABK Biomedical recently unveiled the groundbreaking Eye90 microspheres device designed to treat individuals diagnosed with unresectable Hepatocellular Carcinoma (HCC).
The Eye90 microspheres signify a crucial advancement in radioembolization technology, offering the potential for substantial enhancements in patient outcomes. This innovation marks a significant breakthrough in the treatment landscape for Hepatocellular Carcinoma (HCC).
This cutting-edge medical device empowers to utilise multi-modality imaging, enabling precise and controlled visual administration while providing personalised dosimetry. This incredible capability presents an opportunity for significant advancement in the realm of Y90 radioembolization.
Eye90 radioembolization stands as a progressive stride in liver-directed therapy for HCC. Leveraging multi-modality imaging, controlled visible administration, and personalised dosimetry, Eye90 microspheres are driving forward the landscape of radioembolization.
Eye90 stands as the pioneering and singular in-procedure imageable Y90 microspheres device. The ongoing clinical trial aims to evaluate the effectiveness and safety of Eye90 microspheres among patients diagnosed with unresectable HCC.
ABK Biomedical has received the breakthrough device designation from the U.S. Food and Drug Administration (FDA) for Eye90 microspheres® device.
